Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Gastrostomy (PEG Tube)
Treatment for Motor neuron disease
Typical Dosage: N/A (procedural)
Effectiveness
85%
Safety Score
70%
Clinical Trials
5
Participants
2.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
N/A (procedural)
Time to Effect
Immediate for nutritional support, long-term for aspiration prevention and quality of life
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$2,000
Side Effect Mgmt:$500
Total Annual:$2,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$35,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$2,778
Comparison vs No Gastrostomy
Cost Difference
+$2,500/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Gastrostomy (PEG Tube) in Motor neuron disease
Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS
NCT06609213RECRUITINGNA
22 participants
INTERVENTIONAL
Fort Lauderdale, United States
Started: Jan 10, 2025
Completed Clinical Trials
3 completed trials for Gastrostomy (PEG Tube) in Motor neuron disease
High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis
NCT00983983COMPLETEDPHASE2
28 participants
INTERVENTIONAL
Phoenix, United States +12 more
Started: Oct 1, 2009
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
NCT02908685COMPLETEDPHASE2
231 participants
INTERVENTIONAL
Palo Alto, United States +44 more
Started: Oct 19, 2016
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)
NCT02628743COMPLETEDPHASE2
131 participants
INTERVENTIONAL
Ghent, Belgium +23 more
Started: Jan 20, 2016